Moximed

Moximed is a medical device company based in Fremont, California, dedicated to improving the standard of care for people with knee osteoarthritis (OA). The company's flagship product is the MISHA Knee System, an implantable shock absorber (ISA) for the knee. Developed over more than a decade of clinical research, the MISHA Knee System received FDA de novo marketing authorization in April 2023 for treating medial knee OA. The system is designed for patients who have failed to find relief from non-surgical or surgical treatments and continue to experience pain that interferes with daily activities, but are ineligible for or unwilling to undergo joint replacement due to age or absence of advanced OA.

The MISHA Knee System works by reducing the weight load on the knee joint during walking. Implanted on the medial knee through an outpatient procedure, it moves with the natural joint and reduces about 30% of the peak force on the knee with each step. This reduction in force has been shown to alleviate pain, improve function, and potentially delay the need for total knee replacement in some patients. In its Calypso pivotal study, Moximed demonstrated the superiority of MISHA over high tibial osteotomy, a well-established surgery for knee OA.

Key customers and partnerships

Moximed's MISHA Knee System targets the large and growing population of knee OA sufferers in the US. As of 2023, over 32 million adults in the US were affected by OA, with projections indicating this number could reach 70 million by 2040. The company has seen significant interest from both surgeons and patients since receiving FDA clearance. In September 2023, Moximed announced the completion of the first commercial cases of the MISHA Knee System, with procedures performed at top-tier academic centers and high-caliber private practices across the country.